ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Acta Anaesthesiologica Scandinavica

Acta Anaesthesiologica Scandinavica

Volume 48 Issue 6, Pages 790 - 792

Published Online: 11 Jun 2004

Journal compilation © 2010 The Acta Anaesthesiologica Scandinavica Foundation



< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: HTML, PDF (Size: 65K)  | Related Articles | Citation Tracking

Case Report
Successful treatment with enoximone for severe poisoning with atenolol and verapamil: a case report
C. Sandroni 1 *, F. Cavallaro 1 , C. Addario 2 , G. Ferro 1 , F. Gallizzi 3 and M. Antonelli 1
  1 Department of Anesthesiology and Intensive Care, and   2 Poison Control Center, Catholic University School of Medicine, Rome, and   3 Department of Anesthesiology and Intensive Care, Ospedale Maggiore della Carità, Novara, Italy
Correspondence to   *Dr Claudio Sandroni
Department of Anesthesiology and Intensive Care
Catholic University School of Medicine
Largo Gemelli 8–00168
Rome
Italy
Copyright Acta Anaesthesiol Scand, 2004
KEYWORDS
Antidotes • atenolol • cardiogenic shock • enoximone • poisoning • verapamil

ABSTRACT

Combined poisoning with calcium channel blockers (CCBs) and beta-blockers is usually associated with severe hypotension and heart failure. Due to the block of the beta receptors, treatment with adrenergic agonists, even at high doses, can be insufficient, and beta-independent inotropes, such as glucagon, may be required. Phosphodiesterase III (PDEIII) inhibitors represent a possible alternative to glucagon in these cases as they have an inotropic effect which is not mediated by a beta receptor.


Accepted for publication 4 February 2004

DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.0001-3072.2004.00398.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


ESA 2010 - Register Now
Sign Up Now
Sign Up Now
Submit your article today
Sign Up Now
Wiley Medical Twitter
Sign Up Now

Sign Up Now

Be the first to know about new research in your field

Sign up for FREE e-alerts from Wiley-Blackwell journals!

Sign Up Now